Disclosed are novel aromatic compounds which are useful for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are and pharmaceutical compositions containing, intermediate compounds and processes of making such compounds.
Disclosed are novel aromatic compounds of the formula (I) wherein G, X, Ar, L and Q are defined herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.
1
The present invention relates to compounds of formula (I) for use as pharmaceutical active compounds, as well as pharmaceutical formulations containing the same, for the treatment of allergic diseases.
本发明涉及式(I)的化合物,用作药物活性化合物,以及包含相同化合物的制药配方,用于治疗过敏性疾病。
THERAPEUTIC COMPOUNDS AND USES THEREOF
申请人:Constellation Pharmaceuticals, Inc.
公开号:US20160158207A1
公开(公告)日:2016-06-09
The present invention relates to compounds of formula (I) or formula (II):
and to salts thereof, wherein R
1
-R
4
of formula (I) and R
1
-R
3
of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND
申请人:Samsung Electronics Co., Ltd.
公开号:US20220081457A1
公开(公告)日:2022-03-17
Provided are an organometallic compound represented by Formula 1, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound:
M
1
(L
11
)
n11
(L
12
)
n12
Formula 1
wherein L
11
in Formula 1 is a ligand represented by Formula 1-1:
wherein, in Formula 1-1, Ar
1
is a phenyl group substituted with at least one of E
1
and Ar
2
is a phenyl group substituted with at least one E
2
, and the other substituents are described in the detailed description of the present specification.